---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-305418"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2026-07-16T12:06:47+00:00"
generated_at: "2026-07-16T12:10:05.824029+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# enGene chairman Glickman resigns; Heffernan appointed chair; BLA submission planned for 2H 2026

## Summary
- Dr. Richard Glickman resigned as director and chairman effective July 15, 2026; no disagreement.
- Michael Heffernan appointed as chairman; he has over 30 years biopharma experience.
- Pre-BLA meeting with FDA and BLA submission for detalimogene planned for 2H 2026.
- Potential FDA approval of detalimogene in 2027.
- Detalimogene is being evaluated in Phase 2 LEGEND trial for high-risk NMIBC.

## SEC filing metadata
- accession: 0001193125-26-305418
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2026-07-16T12:06:47+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312526305418/0001193125-26-305418-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312526305418/engn-20260715.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-305418
- JSON: https://secwatch.observer/filing/0001193125-26-305418.json
- Plain text: https://secwatch.observer/filing/0001193125-26-305418.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.